Treatment efficacy and prognostic factors in patients (pts) with malignant ovarian germ cell tumors (MOGCT): Single-center experience

Date

08 Oct 2016

Session

Poster Display

Presenters

Dzhennet Chekini

Citation

Annals of Oncology (2016) 27 (6): 296-312. 10.1093/annonc/mdw374

Authors

D. Chekini1, A. Tryakin1, M. Fedyanin1, A. Bulanov1, M. Ahmedova2, I. Pokataev1, T. Zakharova3, S. Tjulandin1

Author affiliations

  • 1 Clinical Pharmacology And Chemotherapy, N. N. Blokhin Russian Cancer Research Center, 115478 - Moscow/RU
  • 2 Ultrasound Diagnostics, N. N. Blokhin Russian Cancer Research Center, 115478 - Moscow/RU
  • 3 Pathology, N. N. Blokhin Russian Cancer Research Center, 115478 - Moscow/RU
More

Resources

Background

to evaluate the long-term survival and clinicopathologic factors in pts after treatment for MOGCT.

Methods

A total of 163 pts treated for MOGCT in our center between 1987-2015 were included into this retrospective study. Clinical data including symptoms, demographics, stage, surgery, chemotherapy, survival were collected from medical records and assessed in univariate analysis.

Results

The median age was 21 years (range, 12-49 years). 109 (66.9%) of 163 underwent fertility-preserving surgery followed by chemotherapy. Histologically (n = 159) 27.7% of cases were pure dysgerminoma, in 4 pts histologic data were not available. 129 (79%) pts received BEP regimen as a first line treatment, and 34 (20.9%) treated with other regimens. 13 (8%) pts had gonadal dysgenesis. With median follow-up of 88 month (range 1-337 month) 10-year OS was 84% and 48 (29.4%) pts had disease recurrence. The 5-year disease free survival in pts with dysgerminoma and non-dysgerminoma was 87% and 66% respectively (HR 0.45, p = .04). BEP regimen was significantly superior to non-BEP regimen in 10-year OS (94% vs 55%, HR 7.1, p

Conclusions

Comprehensive surgical staging was associated with a lower rate of recurrence. Pts with negative prognostic factors perhaps need more aggressive therapy. It requires additional studies for improvement of therapeutic strategy.

Clinical trial identification

not applicable

Legal entity responsible for the study

N/A

Funding

Budget of clinic

Disclosure

All authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings